程序性死亡配体1的18F PET活体显像
研究用18F标记结合PD-L1的Affibody分子NOTA-ZPD-L1_1,在PD-L1阳性、阴性和混合肿瘤的严重联合免疫缺陷小鼠中行90分钟动态PET及离体分布、放射自显影与免疫组化比较。结果显示标记物放化产率15.1%±5.6%、放化纯度96.7%±2.0%、比活度14.6±6.5 GBq/μmol,表面等离子共振测得结合亲和力1 nM;PD-L1阳性肿瘤摄取快且滞留明显,阴性肿瘤滞留少,阳性肿瘤%ID/g=2.56±0.33 vs 阴性0.32±0.05(P=0.0006),离体放射自显影与免疫组化空间分布高度一致。
要点
- 18F标记的Affibody分子NOTA-ZPD-L1_1放化产率15.1%±5.6%、放化纯度96.7%±2.0%、比活度14.6±6.5 GBq/μmol。
- PD-L1阳性肿瘤%ID/g=2.56±0.33 vs 阴性0.32±0.05(P=0.0006),阳性肿瘤摄取快、阴性滞留少。
- 离体放射自显影与抗PD-L1抗体(22C3)免疫组化在混合肿瘤中空间分布高度一致。
核心结论
- Affibody配体可在活体有效靶向肿瘤PD-L1,具有良好特异性和快速清除。
- 未来研究将探索减少肾脏放射性滞留并进一步提高肿瘤摄取的方法。
研究设计与样本
- 用18F标记PD-L1结合Affibody分子NOTA-ZPD-L1_1,并在体外及体内评价其结合亲和力、靶向性和特异性。
- 体内研究在荷PD-L1阳性、PD-L1阴性和混合肿瘤的严重联合免疫缺陷小鼠中进行,经尾静脉注射示踪剂后行90分钟动态PET扫描,随后行γ计数生物分布。
- 用抗PD-L1抗体(22C3)行免疫组化评估肿瘤PD-L1分布,并与相邻组织切片的离体放射自显影图像比较。
主要发现
- NOTA-ZPD-L1_1标记的放化产率为15.1%±5.6%,放化纯度为96.7%±2.0%,比活度为14.6±6.5 GBq/μmol。
- 表面等离子共振显示NOTA偶联配体的结合亲和力为1 nM。
- PET显像显示示踪剂在PD-L1阳性肿瘤中快速摄取,而PD-L1阴性对照肿瘤示踪剂滞留很少。
- 示踪剂从多数器官和血液中清除快,生物分布显示肾脏滞留明显、肝脏摄取低。
- PD-L1阳性肿瘤的每克注射剂量百分比(%ID/g)=2.56±0.33 vs PD-L1阴性肿瘤0.32±0.05(P=0.0006);离体放射自显影与免疫组化在混合肿瘤中空间相关性极好。
关键数值与推荐
- PD-L1阳性肿瘤%ID/g=2.56±0.33 vs PD-L1阴性肿瘤0.32±0.05(P=0.0006)。
- NOTA-ZPD-L1_1放化产率15.1%±5.6%、放化纯度96.7%±2.0%、比活度14.6±6.5 GBq/μmol。
- NOTA偶联配体结合亲和力为1 nM。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文结论指出未来研究将探索减少肾脏放射性滞留并进一步提高肿瘤摄取的方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Programmed death ligand 1 (PD-L1) is an immune regulatory ligand that binds to the T-cell immune check point programmed death 1. Tumor expression of PD-L1 is correlated with immune suppression and poor prognosis. It is also correlated with therapeutic efficacy of programmed death 1 and PD-L1 inhibitors. In vivo imaging may enable real-time follow-up of changing PD-L1 expression and heterogeneity evaluation of PD-L1 expression across tumors in the same subject. We have radiolabeled the PD-L1-binding Affibody molecule NOTA-ZPD-L1_1 with 18F and evaluated its in vitro and in vivo binding affinity, targeting, and specificity. Methods: The affinity of the PD-L1-binding Affibody ligand ZPD-L1_1 was evaluated by surface plasmon resonance. Labeling was accomplished by maleimide coupling of NOTA to a unique cysteine residue and chelation of 18F-AlF. In vivo studies were performed in PD-L1-positive, PD-L1-negative, and mixed tumor-bearing severe combined immunodeficiency mice. Tracer was injected via the tail vein, and dynamic PET scans were acquired for 90 min, followed by γ-counting biodistribution. Immunohistochemical staining with an antibody specific for anti-PD-L1 (22C3) was used to evaluate the tumor distribution of PD-L1. Immunohistochemistry results were then compared with ex vivo autoradiographic images obtained from adjacent tissue sections. Results: NOTA-ZPD-L1_1 was labeled, with a radiochemical yield of 15.1% ± 5.6%, radiochemical purity of 96.7% ± 2.0%, and specific activity of 14.6 ± 6.5 GBq/μmol. Surface plasmon resonance showed a NOTA-conjugated ligand binding affinity of 1 nM. PET imaging demonstrated rapid uptake of tracer in the PD-L1-positive tumor, whereas the PD-L1-negative control tumor showed little tracer retention. Tracer clearance from most organs and blood was quick, with biodistribution showing prominent kidney retention, low liver uptake, and a significant difference between PD-L1-positive (percentage injected dose per gram [%ID/g] = 2.56 ± 0.33) and -negative (%ID/g = 0.32 ± 0.05) tumors (P = 0.0006). Ex vivo autoradiography showed excellent spatial correlation with immunohistochemistry in mixed tumors. Conclusion: Our results show that Affibody ligands can be effective at targeting tumor PD-L1 in vivo, with good specificity and rapid clearance. Future studies will explore methods to reduce kidney activity retention and further increase tumor uptake.
引用
- González Trotter DE, Meng X, McQuade P, et al. In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET. J Nucl Med. 2017. PMID: 28588151. doi:10.2967/jnumed.117.191718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。